MERZ on the Move: Days After Ulthera Acquisition, Company Announces Plans for New Retinoid Therapy
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
The serum was shown to improve skin brightness, roughness, and tone in a 12-week clinical study of patients with mild-to-severe pigmentation.